Q3 2024 Earnings Call Transcript October 25, 2024 Sanofi beats earnings expectations. Reported EPS is $1.57, expectations ...

Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...

Respiratory season is among us, and Respiratory Syncytial Virus immunizations are now available for older adults and pregnant ...

On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...

The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, ...

Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full ...

On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), ...

Starting Nov. 4, babies born in 2024 can get Beyfortus — also known as nirsevimab — to protect against severe illness from ...

Investing.com -- Sanofi (EPA: SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by ...

This content was published on Oct 26, 2024 The Swiss Federal Democratic Union (EDU) has handed in referendum signatures to seek a vote to prevent the Eurovision Song Contest (ESC) from taking ...

Olympic gold medalist gymnast Shawn Johnson East had respiratory syncytial virus-related experiences with all 3 of her ...